CD34 and chronic myelogenous leukemia, BCR-ABL1 positive: Potentially of greater interest, we also established that DIF-3 preferentially eradicates CD34+ CML cells relative to its effect on CD34− cells, indicating a better selectivity for leukemic than normal myeloid precursors.